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SUMMARY – Although the in vitro fertilization-intra-cytoplasmic sperm injection (IVF-ICSI) 
has been utilized widely, the management in patients with an autoimmune disease is still a challenge. 
Th e aim of this study was to demonstrate IVF-ICSI outcomes in infertile women with familial 
 Mediterranean fever (FMF). Patient data were collected from the cases registered from January 2006 
until January 2014. A total of 6152 assisted reproductive technology (ART) cycles were analyzed 
retrospectively in the Ankara Zekai Tahir Burak Women’s Health Education and Research Hospital. 
Ten infertile women with FMF were included in the study. Baseline clinical and laboratory character-
istics were collected and perinatal outcomes evaluated. Th e mean age (years), duration of infertility 
(years) and body mass index (kg/m2) were 29.9±5.3, 5.7±5.3 and 27.9±5.7, respectively. Th e mean 
baseline follicle-stimulating hormone (FSH; IU/L), estradiol (E2; pg/mL) and antral follicle count 
were 7.0±2.4, 48.1±15.8 and 7.9±2.9, respectively. Th e distribution of ovarian response was heteroge-
neous. Fourteen cycles in ten patients were evaluated. Embryo transfer could be achieved in only ten 
cycles. Th ree out of ten patients became pregnant. No adverse perinatal outcome was observed. Our 
fi ndings indicate that FMF might have no impact on ART cycles.
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Introduction
Although the in vitro fertilization-intra-cytoplas-
mic sperm injection (IVF-ICSI) has been utilized 
widely, the management in patients with an autoim-
mune disease is still a challenge. Numerous mecha-
nisms could lead to infertility such as premature ovar-
ian failure, harmful eff ects of antibodies on implanta-
tion and fertilization, autoimmune oophoritis, etc. 
Also, antibodies may lead to placental damage, im-
mune rejection, and recurrent pregnancy failure1,2.
Familial Mediterranean fever (FMF) is an autoso-
mal recessive disorder characterized by recurrent fever 
attacks and abdominal pain. It aff ects mainly Jewish, 
Armenian, and Turkish people. In these populations, 
the incidence of the disease has been documented as 
being 1/500-1/10003. In accordance with the inci-
dence of FMF in Turkish population, the 10 women 
cohort was accepted as normal. FMF occurs due to a 
mutation in the Mediterranean fever (MEFV) gene. 
Th e pyrin protein which is expressed by MEFV gene 
leads to a decrease in the infl ammatory mediator lev-
els. Th erefore, an abnormality of the gene can lead to 
an increase in infl ammatory response4-7.
Th e IVF-ICSI has been utilized all over the world 
for more than three decades now. However, the man-
agement of IVF-ICSI in FMF patients remains a 
challenge for clinicians. Although there are many pub-
lished studies about the infl uence of FMF on infertil-
ity, the association between FMF and IVF-ICSI out-
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come is still controversial7. Th e relationship between 
infertility and FMF was fi rst introduced by Ismajo-
vitch et al.8. Th ey claimed that FMF could cause infer-
tility due to ovulatory dysfunction in up to 87% of 
cases. Dor et al. report that oligomenorrhea was more 
common in FMF group than in the general population 
(46% vs. 31%)9. Unfortunately, the reason for oligo-
menorrhea is not known. In the same study, interest-
ingly, the pelvic adhesion rate was found to be similar 
in FMF and control groups, i.e. 31% and 28%, respec-
tively9. Yasar et al. report on retrospective evaluation 
of 46 pregnant women with FMF, claiming that 
FMF increased the premature rupture of membranes 
(PROM), recurrent miscarriages, and preterm delivery 
rates10.
Th e mechanisms of infertility and impact on peri-
natal outcome due to FMF remains unclear11. Th ere-
fore, we aimed to assess whether there is infl uence of 
FMF on IVF outcome.
Material and Methods
Study design
Th e aim of this retrospective cohort study was to 
analyze our assisted reproductive technology (ART) 
cycle results in FMF patients. Th e study protocol was 
approved and ethical consent granted by the local Eth-
ics Committee. Patient data were collected from the 
cases registered from January 2006 until January 2014. 
A total of 6152 women admitted to our IVF unit were 
evaluated. Ten infertile FMF women having under-
gone 14 ART cycles were included in the study.
Th e diagnosis of FMF was made by an internal 
specialist according to clinical symptoms such as inter-
mittent fever, recurrent abdominal pain, family history, 
and the complaints subsiding with colchicine treat-
ment. All study women were receiving colchicine. Col-
chicine (Colchicum dispert®, 0.5 mg tbl, Recordati, 
Turkey) was administered at a dose of 0.5 mg b.i.d. to 
suppress FMF attacks.
Gonadotropin stimulation for ART, 
oocyte retrieval and sample collection
Agonist and antagonist protocols were used for 
controlled ovarian hyperstimulation (COH) individu-
ally. Flexible daily gonadotropin releasing hormone 
(GnRH) antagonist protocol was preferred to induce 
pituitary down-regulation (Cetrotide 0.25 mcg, Sero-
no, Switzerland). A dose of 150-225 U daily rec-FSH 
(Gonal-F, Serono, Istanbul) and/or human menopaus-
al gonadotropin (HMG) (Menogon, Ferring, Switzer-
land) were started on day 3 of the cycle and continued 
for the fi rst 3 days of stimulation, after which daily 
dosing was determined individually. Th e GnRH an-
tagonist was started when the leading follicle reached 
a diameter of 12-14 mm. Serial estradiol (E2) levels 
and two-dimensional follicle measurements by trans-
vaginal ultrasound imaging (LOGIC 200 PRO, Gen-
eral Electric, Korea) were performed until at least two 
dominant follicles reached 18 mm or greater in diam-
eter. Human chorionic gonadotropin (Pregnyl, 10,000 
U, im, Organon, Th e Netherlands) was administered, 
followed by transvaginal oocyte retrieval 36 h later. 
ICSI was performed in all patients according to our 
clinical practice. Luteal phase support was routinely 
administered as progesterone in the form of Crinone 
8% gel (Serono, Istanbul), 90 mg daily for 14 days, 
when a pregnancy test was performed. Clinical preg-
nancy was diagnosed by ultrasound demonstration of 
heartbeat in the intrauterine gestational sac. Ongoing 
pregnancies were followed at our perinatology depart-
ment. Data on perinatal outcomes were obtained from 
hospital records.
Statistical analysis
Statistical analysis was performed using the SPSS 
15.00 (SPSS Inc., Chicago, IL, USA). Descriptive 
analysis was performed.
Results
Ten patients were included in the study. One and 
two cycles were performed in 6 and 4 women, respec-
tively. Th e mean age (years), duration of infertility 
(years) and body mass index (kg/m2) were 29.9±5.3, 
5.7±5.3 and 27.9±5.7, respectively. Th e mean baseline 
follicle stimulating hormone (FSH; IU/L), E2 (pg/
mL) and antral follicle count were 7.0±2.4, 48.1±15.8 
and 7.9±2.9, respectively. Demographic and clinical 
characteristics of study patients are shown in Table 1.
Age, baseline FSH and E2 levels, total gonadotro-
pin dose, peak E2 level, endometrial thickness, re-
trieved oocytes, metaphase II (M II) oocytes, 2 pro-
nucleus (2 PN), transferred embryo number, and clini-
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cal pregnancy rate for each patient are shown in Table 
2. Th e causes of infertility were male factor in 4 (40%), 
unexplained in 3 (30%), poor ovarian reserve in 2 
(20%) cases, and tubal factor in 1 (10%) case. Th e dis-
tribution of ovarian response was heterogeneous. En-
dometrial thickness was found to be within the normal 
range. Fertilization failure occurred in two patients 
without male factor. Embryo transfer could be achieved 
in only ten cycles. Preimplantation genetic diagnosis 
was not performed because of the patients’ choice.
Clinical pregnancy occurred in three women. All 
these pregnancies were followed at perinatology de-
partment. Th ere were no problems throughout preg-
nancy and newborns were healthy. Th e mode of deliv-
ery was cesarean section in all three women. Th e birth 
weight of the babies was 3020 g, 2400 g and 3550 g.
Discussion
In this study, records of ten infertile women with 
FMF admitted to the IVF unit of Ankara Zekai Tahir 
Burak Women’s Health Education and Research Hos-
pital were reviewed retrospectively. Th ree of ten pa-
tients became pregnant. As mentioned above, a total of 
6152 women were admitted to our IVF unit and 10 
FMF cases were detected. Th ese ratios were consistent 
with the literature.
Familial Mediterranean fever is a chronic disease 
and the relationship between FMF and infertility is 
not clear. Various mechanisms could contribute to in-
fertility in patients with FMF. Oligomenorrhea and 
pelvic adhesions (due to recurrent peritoneal infl am-
mation) are the main causes of infertility in FMF8,9. 
Colchicine has been utilized for the treatment of FMF 
since 1974. Colchicine reduces infertility rates as a re-













ON M II 2 PN TEN
Clin.
pregn. FSHX E2Y
1 24 6.6 32 10 2000 12 4370 14 10 3 1 (-)
1a 25 5 64 15 1625 12 2220 1 1 0 0 (-)
2 36 5.5 30 5 2925 9 1408 8 4 3 2 (-)
3 35 8.8 49 5 4950 13 782 2 2 0 0 (-)
4 31 10.6 52 10 4500 11 1038 2 3 1 1 (-)
5 23 9 79 6 2250 9 3587 12 12 7 1 (+)
6 28 5 44 14 1150 9 3049 17 12 8 1 (-)
6a 30 7 35 9 1100 7 2339 17 6 5 1 (+)
7 31 6.5 59 13 1687 12 2088 8 7 3 1 (+)
8 31 7.5 28 15 1650 10 2766 21 17 9 1 (-)
9 24 2.3 43 19 1520 8 1650 11 6 4 1 (-)
9a 25 7 47 9 1400 7 1530 12 10 8 1 (-)
10 38 10.6 62 5 4500 8.5 985 1 1 0 0 (-)
10a 38 7 50 5 300 7.5 365 4 1 1 0 (-)
IVF-ICSI = in vitro fertilization-intra-cytoplasmic sperm injection; FSH = follicle-stimulating hormone; E2 = estradiol; AFC = antral 
follicle count; ON = oocyte count; M II = metaphase II oocyte; Total gnd. dose = total gonadotropin dose; 2 PN = 2 pronucleus; End. thick. 
= endometrial thickness; TEN = transferred embryo number; Clin. pregn. = clinical pregnancy; X IU/L; Y pg/mL; a second cycle
Table 1. Patient characteristics
Patients (n=10) p value
Age (yrs) 29.9±5.3 NA
Duration of infertility (yrs) 5.7±5.3 NA
Baseline FSH (IU/L) 7.0±2.4 NA
Baseline LH (IU/L) 6.2±2.0 NA
Baseline E2 (pg/mL) 48.1±15.8 NA
AFC (number) 7.9±2.9 NA
BMI (kg/m2) 27.9±5.7 NA
FSH = follicle-stimulating hormone; LH = luteinizing hormone; 
E2 = estradiol; AFC = antral follicle count; BMI = body mass in-
dex; NA = not applicable
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sult of cessation of FMF attacks. However, this drug 
could deteriorate sperm functions and numerical 
anomalies such as oligospermia and azoospermia. But, 
these side eff ects are rarely seen11,12.
Ehrenfeld et al.13 investigated fertility and obstetric 
history of 36 women with FMF. All the patients were 
also receiving colchicine treatment. Th irteen (36%) 
women had infertility. Th e causes of infertility were 
ovulatory dysfunction in 6 (46%), peritoneal adhesion 
in 4 (31%) and unexplained in 3 (23%) cases. However, 
the limitation of that study was absence of serum hor-
mone levels such as FSH, luteinizing hormone and 
E213. In our study, serum hormone levels were deter-
mined and three patients had oligomenorrhea. Th ere 
are confl icting data about FMF and its infl uence on 
infertility. Mamou et al.14 report that FMF could lead 
to ovarian insuffi  ciency. In the present study, poor 
ovarian response was observed in three patients. On 
the contrary, Zayed et al.15 found that the causes of 
infertility in FMF were the same as in the general 
population.
In the light of these data, there is still debate on 
this issue. Unfortunately, the drawbacks of these stud-
ies were small sample sizes and heterogeneity of the 
populations.
In conclusion, our results indicated that baseline 
clinical and laboratory characteristics were variable as 
in the general infertile population. FMF could cause 
infertility via diff erent mechanisms. In the present 
study, although the spectrum of the ovarian reserves 
was variable, we detected similar live birth rates as pre-
viously reported. Our study showed that FMF might 
have no negative impact on ART cycles.
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Sažetak
UTJECAJ OBITELJSKE MEDITERANSKE VRUĆICE NA ISHOD IZVANTJELESNE OPLODNJE: 
RETROSPEKTIVNA ANALIZA NIZA SLUČAJEVA
N. Karakas Yilmaz, M. Kara, M. Kaba, B. Coskun, S. Erkilinc i S. Erkaya
Iako je metoda oplodnje in vitro i intracitoplazmatskog injektiranja sperme (in vitro fertilization-intra-cytoplasmic sperm 
injection, IVF-ICSI) danas široko rasprostranjena u čitavom svijetu, njezina primjena u bolesnica s autoimunim bolestima još 
uvijek predstavlja velik izazov. Cilj ovoga istraživanja bio je pokazati ishode IVF-ICSI kod neplodnih žena s obiteljskom 
mediteranskom groznicom (familial Mediterranean fever, FMF). Podaci bolesnica prikupljeni su iz registriranih slučajeva od 
siječnja 2006. do siječnja 2014. godine. Retrospektivna analiza provedena u Zekai Tahir Burak Women’s Health Education 
and Research Hospital u Ankari obuhvatila je 6152 ciklusa potpomognute oplodnje (assisted reproductive technology, ART). 
U istraživanje je bilo uključeno deset neplodnih žena s FMF. Uzeti su bazalni podaci o kliničkim i laboratorijskim značajka-
ma uključenih žena, kao i perinatalnim ishodima. Srednje vrijednosti dobi (godine), trajanja neplodnosti (godine) i indeksa 
tjelesne mase (kg/m2) bile su 29,9±5,3; 5,7±5,3 odnosno 27,9±5,7. Srednje vrijednosti folikul-stimulirajućeg hormona (FSH; 
IU/L), estradiola (E2; pg/mL) i broja antralnih folikula bile su 7,0±2,4; 48,1±15,8 odnosno 7,9±2,9. Raspodjela ovarijskog 
odgovora bila je heterogena. Procijenjeno je 14 ciklusa u deset žena. Transfer embrija bio je moguć u samo deset ciklusa, a 
trudnoća je postignuta u tri od deset žena. Nije zabilježen nikakav štetni perinatalni ishod. Naši nalazi ukazuju na to da FMF 
možda nema nikakvog utjecaja na cikluse ART.
Ključne riječi: Obiteljska mediteranska vrućica; Neplodnost; Fertilizacija, in vitro; Sperma, intracitoplazmatske injekcije; 
Trudnoća
